Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab.
暂无分享,去创建一个
[1] J. Ko,et al. Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab. , 2019, JAMA dermatology.
[2] T. Bieber,et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials , 2019, The British journal of dermatology.
[3] F. Sallusto,et al. The Skin Commensal Yeast Malassezia Triggers a Type 17 Response that Coordinates Anti-fungal Immunity and Exacerbates Skin Inflammation. , 2019, Cell host & microbe.
[4] G. Yancopoulos,et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.
[5] J. Silverberg,et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.
[6] M. Bechtel,et al. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. , 2009, Journal of the American Academy of Dermatology.